NCT03218995View on ClinicalTrials.gov

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 16, 2017

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Eteplirsen

Infusion for intravenous use.

Trial Locations (4)

9000

Universitair ziekenhuis Gent, Ghent

75012

Armand-Trousseau Hospital, Paris

Unknown

Site Fondazione Policlinico Universitario Agostino Gemelli, Roma

WC1N 1EH

UCL Great Ormond Street Institute of Child Health, London

All Listed Sponsors
lead

Sarepta Therapeutics, Inc.

INDUSTRY

NCT03218995 - Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping | Biotech Hunter | Biotech Hunter